ObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.com

Posted by on Mar 18th, 2025

StockNews.com assumed coverage on shares of ObsEva (NASDAQ:OBSV – Free Report) in a research note released on Saturday. The firm issued a hold rating on the stock.

ObsEva Stock Performance

ObsEva has a one year low of $0.08 and a one year high of $2.14. The company has a market cap of $7.94 million, a price-to-earnings ratio of -0.11 and a beta of 0.68.

ObsEva Company Profile

(Get Free Report)

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Further Reading

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.